Tagged with J

APAC A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest its China neurology and allergy business for USD 680 million; and Pfizer, AstraZeneca and Novartis investing in Singaporean manufacturing.  …

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Saudi Arabia Noncommunicable diseases are the leading cause of death and disability worldwide, accounting for 74 percent of all deaths and more than three out of four years lived with a disability. These chronic conditions – which cannot be transmitted from person to person and often require long-term or lifelong care –…

Global DIA’s Sorcha McCrohan, contributing to the the August 2024 edition of DIA’s Global Forum magazine, reviews insights from the town hall meetings that brought together regulators from around the world at the organization’s Global Annual Meeting 2024.   Regulators worldwide recently convened in San Diego for DIA’s Global Annual Meeting 2024 to…

APAC A roundup of the biggest pharma stories coming out of APAC, including Eisai’s deal with biotech SEED Therapeutics and share drop after Alzheimer’s rejection in the EU; Mayne Pharma’s lawsuit against Sun; Novo Nordisk’s insulin partnership with Bio Farma, and Celltrion’s resturcturing.   Amid GLP-1 boom, Novo Nordisk strikes up…

Hong Kong Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology milestones, comments on the affiliate’s push to enhance clinical trials in alignment with mainland China, local talent development and the…

China Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a record 63 cross-region out-licensing deals in 2023, and attracting the attention of global pharma. Recent PharmaBoardroom interviewees weigh in on…

Global As pharma navigates issues ranging from the US Inflation Reduction Act to new EU pharmaceutical legislation, and the impact of global unrest on supply chains, the industry is experiencing other shifts as reflected in Pharma Exec’s 2024 Top 50 Companies. Based on 2023 drug revenue performance from global drug makers,…

Japan A roundup of the most important stories coming out of Japan’s pharma industry, including the sharp increase in deaths linked to Kobayashi supplements; the partnership between Moderna and Mitsubishi Tanabe to jointly promote Moderna’s mRNA respiratory vaccine portfolio; the country’s move to to support domestic antibiotics production; Takeda’s licenscing agreement…

Saudi Arabia SAJA Pharmaceuticals is aiming to grow from a regional player to a multinational entity, in line with Saudi Arabia’s Vision 2030, leveraging strong partnerships, technology transfer, and strategic licensing to expand geographically. CEO Mohammed Khalil explains how the Saudi firm prides itself on its agility and commitment to high-quality, accessible…

Saudi Arabia Faisal Al Tlasi introduces Axantia’s strategic goals, the transformation of Saudi Arabia’s healthcare system, and the company’s role in supporting Vision 2030. He discusses the importance of expanding the company’s product portfolio, entering new markets, and enhancing employee capabilities. Emphasizing partnerships and regulatory advancements, Al Tlasi underscores Axantia’s commitment to…

Japan Writing in DIA’s Global Forum magazine for June 2024, Mamoru Narukawa of Kitasato University Graduate School of Pharmaceutical Sciences takes a look at some of the positive trends impacting Japan’s drug pricing system.   Drug expenditure as a percentage of healthcare costs in Japan has been stable at approximately 22% in…